Baricitinib vs Ipilimumab
Baricitinib vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Baricitinib and Ipilimumab.
Mechanism of Action
Baricitinib: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Baricitinib — 12 hours; Ipilimumab — 14.7 days.
Chemical Properties
Molecular Formula: Baricitinib — C16H17N7O2S.
Molecular Weight: Baricitinib — 371.4170 g/mol.
Type: Baricitinib — Small molecule; Ipilimumab — Antibody.